These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9440632)

  • 41. One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group.
    Misiewicz JJ; Harris AW; Bardhan KD; Levi S; O'Morain C; Cooper BT; Kerr GD; Dixon MF; Langworthy H; Piper D
    Gut; 1997 Dec; 41(6):735-9. PubMed ID: 9462204
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials.
    Peura DA; Kovacs TO; Metz DC; Siepman N; Pilmer BL; Talley NJ
    Am J Med; 2004 Jun; 116(11):740-8. PubMed ID: 15144910
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter pylori-associated duodenal ulcer.
    Lazzaroni M; Bargiggia S; Bianchi Porro G
    Am J Gastroenterol; 1997 Apr; 92(4):649-52. PubMed ID: 9128316
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of omeprazole combined with antibiotics for Helicobacter pylori eradication and duodenal ulcer recurrence.
    Lazzaroni M; Maconi G; Bargiggia S; Minguzzi M; Bianchi Porro G
    Eur J Gastroenterol Hepatol; 1995 Feb; 7(2):117-9. PubMed ID: 7712301
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Does the depth of gastric ulceration influence a modified dual therapy with amoxicillin and lansoprazole for Helicobacter pylori-associated gastric ulcer?
    Okai T; Ohtsubo K; Sakai J; Watanabe H; Motoo Y; Kawashima A; Sawabu N
    Can J Gastroenterol; 2000 Oct; 14(9):761-6. PubMed ID: 11064311
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Acute treatment of duodenal ulcer: experience with lansoprazole.
    Mignon M; Vallot T
    Aliment Pharmacol Ther; 1993; 7 Suppl 1():37-40, discussion 61-6. PubMed ID: 8490078
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer.
    Florent C
    Clin Ther; 1993; 15 Suppl B():14-21. PubMed ID: 7911399
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Relapse of duodenal ulcers after successful eradication of Helicobacter pylori in gastric ulcer patients.
    Sou Y; Saita H; Takahashi Y; Yoshinaga T; Matsukawa Y; Sekikawa A; Nakazawa T; Shio S; Kohigashi K
    J Gastroenterol; 1999; 34 Suppl 11():84-90. PubMed ID: 10616773
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [A clinical trial of lansoprazole in the treatment of duodenal ulcer].
    Pei Y; Wang B; Chen S
    Zhonghua Nei Ke Za Zhi; 1995 Sep; 34(9):606-8. PubMed ID: 8697927
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lansoprazole versus omeprazole in active duodenal ulcer. A double-blind, randomized, comparative study.
    Ekström P; Carling L; Unge P; Anker-Hansen O; Sjöstedt S; Sellström H
    Scand J Gastroenterol; 1995 Mar; 30(3):210-5. PubMed ID: 7770708
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In treatment of active duodenal ulcer and Helicobacter pylori eradication.
    Yukselen V; Yasa MH; Karaoglu AO
    Hepatogastroenterology; 2003 Dec; 50 Suppl 2():cccvi-cccviii. PubMed ID: 15244210
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Lansoprazole versus ranitidine bismuth citrate containing triple regimens for Helicobacter pylori eradication in patients with duodenal ulcer].
    Buzás György M; Székely E; Illyés G; Széles I
    Orv Hetil; 2000 Jul; 141(31):1711-4. PubMed ID: 10976194
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Helicobacter pylori and digestive hemorrhage due to duodenal ulcer: the prevalence of the infection, the efficacy of 3 triple therapies and the role of eradication in preventing a hemorrhagic recurrence].
    Gisbert JP; Boixeda D; Aller R; de la Serna C; Sanz E; Martín de Argila C; Abraira V; García Plaza A
    Med Clin (Barc); 1999 Feb; 112(5):161-5. PubMed ID: 10091208
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
    Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
    Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Erradicating treatment of Helicobacter pylori with lansoprazole and amoxicillin in duodenal ulcer patients].
    Gisbert JP; Boixeda D; Alvarez Baleriola I; Martín de Argila C; Bermejo F; Aller R
    Rev Clin Esp; 1996 Sep; 196(9):588-93. PubMed ID: 8966319
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial.
    Robinson M; Lanza F; Avner D; Haber M
    Ann Intern Med; 1996 May; 124(10):859-67. PubMed ID: 8610914
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prevention of recurrence of oesophageal stricture, a comparison of lansoprazole and high-dose ranitidine.
    Swarbrick ET; Gough AL; Foster CS; Christian J; Garrett AD; Langworthy CH
    Eur J Gastroenterol Hepatol; 1996 May; 8(5):431-8. PubMed ID: 8804870
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain--a randomized, double-blind, placebo-controlled, crossover trial.
    Bautista J; Fullerton H; Briseno M; Cui H; Fass R
    Aliment Pharmacol Ther; 2004 May; 19(10):1123-30. PubMed ID: 15142202
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dose ranging study of lansoprazole, a new proton pump inhibitor, in patients with high gastric acid secretion.
    Berlin I; Molinier P; Duchier A; Cournot A; Durrel J; Dellatolas F; Duchier J
    Eur J Clin Pharmacol; 1992; 43(2):117-9. PubMed ID: 1425865
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Usefulness of proton pump inhibitor (PPI) maintenance therapy for patients with H. pylori-negative recurrent peptic ulcer after eradication therapy for H. pylori: pathophysiological characteristics of H. pylori-negative recurrent ulcer scars and beyond acid suppression by PPI.
    Ohara T; Morishita T; Suzuki H; Masaoka T; Ishii H
    Hepatogastroenterology; 2004; 51(56):338-42. PubMed ID: 15086153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.